Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy

Clinical Endocrinology

Volumn 71, Issue 4, 2009, Pages 477-484

  Zimmermann, Anca ^a,d   Sido, Paula Grigorescu ^b   Schulze, Egbert ^c   Al Khzouz, Camelia ^b   Lazea, Cecilia ^b   Coldea, Cristina ^b   Weber, Matthias M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Laboratory for Molecular Genetics   (Germany)

^d 1st Clinic for Internal Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PRASTERONE SULFATE; PREDNISONE; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GENOTYPE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MALE; MORNING DOSAGE; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; ROMANIA; SCHOOL CHILD; STEROID 21 MONOOXYGENASE DEFICIENCY; TREATMENT DURATION;

ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; BONE AND BONES; BONE DENSITY; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROCORTISONE; MALE; OSTEOCALCIN; STEROID 21-HYDROXYLASE;

EID: 69949187044     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03518.x     Document Type: Article

References (37)

1. White, P.C. Speiser, P.W. (2000) Congenital adrenal hyperplasia due to 21 hydroxylase deficiency. Endocrine Reviews, 21, 245 291.
2. Morel, Y. Miller, W.L. (1991) Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Advances in Human Genetics, 20, 1 68.
3. New, M.I. Ghizzoni, L. (2003) Congenital adrenal hyperplasia. In : F. Lifschitz ed. Pediatric Endocrinology. 4th edn. Marcel Dekker Inc, NY. 175 178.
4. Miller, L.W. (2002) The adrenal cortex. In : M.A. Sperling ed. Pediatric Endocrinology, 2nd edn. Saunders, Philadelphia, PA. 406 408.
5. Saag, K.G. (2003) Glucocorticoid-induced osteoporosis. Endocrinology Metabolism Clinics of North America, 32, 135 157.
6. Mazziotti, G., Giustina, A., Canalis, E. et al. (2007) Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. Arquivos Brasilieros de Endocrinologia and Metabologia, 51, 1404 1412.
7. Berris, K.K., Repp, A.L. Kleerekoper, M. (2007) Glucocorticoid-induced osteoporosis. Current Opinions in Endocrinology, Diabetes and Obesity, 14, 446 450.
8. Stikkelbroeck, N.M., Oyen, W.J., van der Wilt, G.J. et al. (2003) Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 88, 1036 1042.
9. Christiansen, P., Molgaard, C. Müller, J. (2004) Normal bone mineral content in young adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research, 61, 133 136.
10. Guo, C.Y., Weetman, A.P. Eastell, R. (1996) Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clinical Endocrinology, 45, 535 541.
11. Mora, S., Saggion, F., Russo, G. et al. (1996). Bone density in young patients with congenital adrenal hyperplasia. Bone, 18, 337 340.
12. Jääskeläinen, J. Voutilainen, R. (1996) Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clinical Endocrinology, 45, 707 713.
13. Hagenfeldt, K., Marton Ritzén, E., Ringertz, H. et al. (2000) Bone mass and body composition of adult women with congenital virilizing 21 hydroxylase deficiency after glucocorticoid treatment since infancy. European Journal of Endocrinology, 143, 667 671.
14. Sciannamblo, M., Russo, G., Cuccato, D. et al. (2006) Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 91, 4453 4458.
15. King, J.A., Wisniewski, A.B., Bankowski, B.J. et al. (2006) Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 91, 865 869.
16. Bachelot, A., Plu-Bureau, G., Thibaud, E. et al. (2007) Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research, 67, 268 276.
17. Falhammar, H., Filipsson, H., Holmdahl, G. et al. (2007) Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 92, 4643 4649.
18. Lin-Su, K. New, M.I. (2007) Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia. Annals of the New York Academy of Sciences, 1117, 345 351.
19. Girgis, R. Winter, J.S. (1997) The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 82, 3926 3929.
20. Fleischman, A., Ringelheim, J., Feldman, H.A. et al. (2007) Bone mineral status in children with congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism, 20, 227 235.
21. Cameron, F.J., Kaymakci, B., Byrt, E.A. et al. (1995) Bone mineral density and body composition in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 80, 2238 2243.
22. Paganini, C., Radetti, G., Livieri, C. et al. (2000) Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Hormone Research, 54, 164 168.
23. de Almeida Freire, P.O., de Lemos-Marini, S.H., Maciel-Guerra, A.T. et al. (2003) Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral density. Journal of Bone Mineral Metabolism, 21, 396 401.
24. Chakhtoura, Z., Bachelot, A., Samara-Boustani, D. et al. (2008) Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 158, 879 887.
25. Krone, N., Braun, A., Roscher, A.A. et al. (2000) Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well-defined patients from Southern Germany. Journal of Clinical Endocrinology and Metabolism, 85, 1059 1065.
26. Wilson, R.C., Mercado, A.B., Cheng, K.C. et al. (1995) Steroid 21-hydroxylase deficiency genotype may not predict phenotype. Journal of Clinical Endocrinology and Metabolism, 80, 2322 2329.
27. Bachega, T.A., Billerbeck, A.E., Madureira, G. et al. (1998) Molecular genotyping in Brazilian patients with the classical and nonclassical forms of 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 83, 4416 4419.
28. Ferenczi, A., Garami, M., Kiss, E. et al. (1999) Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 84, 2369 2372.
29. Grigorescu-Sido, A., Weber, M.M., Grigorescu-Sido, P. et al. (2005) 21-Hydroxylase and 11β-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 90, 5769 5773.
30. Miller, W.L. (1991) The adrenal cortex. In : A.M. Rudolph J.I.E. Hofmann, eds. Pediatrics. Appleton & Lange, Norwalk, CT. 1584 1613.
31. Reincken, L. van Oost, G. (1992) Longitudinale Körperentwicklung gesunder Kinder von 0-18 Jahren. Körperlänge/-höhe, Körpergewicht und Wachstumsgeschwindigkeit. Klinische Pädiatrie, 204, 129 133.
32. Greulich, W.W. Pyle, S.I. (1959) Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd edn. Stanford University Press, Stanford.
33. ICGG/International Collaborative/Gaucher Group/Gaucher Registry Annual Report (2006) p. 16/ http://www.lsdregystry.net/gaucherregistry.
34. Filipsson, H., Monson, J.P., Koltowska-Häggström, M. et al. (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism, 91, 3954 3961.
35. Grigorescu-Sido, A., Bettendorf, M., Schulze, E. et al. (2003) Growth analysis in patients with 21-hydroxylase deficiency. Influence of glucocorticoid dosage, age at diagnosis, phenotype and genotype on growth and height outcome. Hormone Research, 60, 84 90.
36. van Staa, T.P., Leufkens, H.G. Cooper, C. (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International, 13, 777 787.
37. Canalis, E., Mazziotti, G., Giustina, A. et al. (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International, 18, 1319 1328.